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Abstract
Xenotransplantation using pig cells, tissues or organs is considered to be a solution to the shortage of human
allotransplants. Pigs have been selected as optimal donor for several reasons, among them physiological and
economical. Before xenotransplantation will be applied broadly in the clinic three hurdles need to be overcome: (i)
rejection due to immune reactions and coagulation dysfunction, (ii) physiological incompatibility and (iii)
microbiological risk. Although some clinical trials have been performed in the past and some are ongoing, most
experience is gained from pig-to-non human primate experiments. To overcome immune rejection, numerous
multitransgenic and knock-down animals were produced or are in preparation. The physiological compatibility is still
badly studied, mainly due to the short survival time of the recipient animals. Last not least, xenotransplantation may
be associated with the risk of transmission of porcine microorganisms. Most of them can be eliminated by
designated pathogen free breeding of the animals; however, porcine endogenous retroviruses (PERVs) represent a
special risk. PERVs are integrated as proviruses in the genome of all pigs, they can be released as viral particles
and infect human cells. An extensive screening program and selection of donor animals with a low expression of
PERV accompanied by the development of different strategies to prevent PERV transmission is therefore requested.
Finally, a broad discussion within the scientific community and the society concerning ethical aspects of
xenotransplantation had been taken place.
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Introduction
Transplantation is a way to treat severe organ and tissue failures.
Organ transplantation has been one of the preeminent successes in the
field of medicine. An experimental procedure 40 years ago, organ
allotransplantation is meanwhile so successful, that there is a shortage
of human organs suitable for transplantation. In Germany for
example, at present 11,000 persons are on the waiting list for a donor
organ, among them 8000 for a kidney, approximately 25% of them will
die being on this list [1]. With the increase in age of the human
population, the need of different types of transplantations is
increasing. For example, pancreas transplantations are applied to treat
diabetes, the failure of the isle T-cells in the pancreas to produce
insulin. Unfortunately, suitable human donor organs are very rare. For
several reasons diabetes has become an epidemic, with the number of
affected people in 2010 of 285 million (6.4% of the world population)
and 382 Million in 2013 [2]. According to the International Diabetes
Federation this number is expected to increase to 439 million by 2030
and 592 million by 2035 [2]. Moreover, because of the many long-term
complications of diabetes, such as kidney and heart disease,
impotence, limb amputations and blindness, treatment for diabetes
accounts for 10% of health-care expenditure in Europe (€25 billion per
annum) [3].
When discussing alternatives to allotransplantation, strategies to
prevent the organ failure are usually neglected. However, prevention
of organ failure is the best and least expensive way to prevent
transplantation and should be enforced. In the case prevention failed,
alternatives to allotransplantation are (i) mechanical devices, which
are under development mainly for the treatment of heart failure, (ii)
tissue engineering and (iii) the stem cell technology. Although
mechanical heart devices have been improved with considerable good
results, they are still expensive and cumbersome [4]. Tissue
engineering and stem cell research are far from producing functioning
differentiated tissues or even vascularized organs composed of
different T-cell types [5]. Therefore, at present xenotransplantation is
considered to be an optimal solution. Pigs have been selected as
donors due to the physiological similarity, the low reproduction time,
the high number of progeny, the possibility to produce cloned and
transgenic pigs as well as the low costs (for details see [6]). Although
non-human primates are immunologically closer to humans, the size
of the organs from monkeys is too small and apes with a suitable organ
size represent endangered species, they have very long gestation times
and a small number of offspring [6]. The selection of the donor species
is also influenced by the potential microbiological risk. It is a subject of
discussion whether the transmission of microorganisms from a related
species (non-human primates) using a closely related receptor is more
effective than the transmission from an unrelated species (pigs) [7].
The transmission of the human T-cell lymphotropic viruses (HTLV)
and the human immunodeficiency viruses (HIV) from non-human
primates to humans was extremely successful for the viruses, partially
due to the presence of the suitable receptors and a similar metabolism
in the infected cells [8,9]. HTLV induces lymphomas and
immunodeficiency, HIV the acquired immunodeficiency syndrome
(AIDS) [10,11]. This does not exclude that transmission from an
unrelated species may be also successful, especially when the receptor
is highly ubiquitous. A well-studied example is the transmission of a
gammaretrovirus closely related to PERV, the Koala retrovirus
(KoRV), which most likely was transmitted from rodents [12,13] or
from bats [14,15] to the koalas in Australia. The KoRV infection is
spreading nation-wide, the infected animals suffer from lymphomas
and chlamydia infection based on a severe immunodeficiency [16-18].
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To summarize, three hurdles need to be overcome before
xenotransplantation can be applied in the clinic: (i) rejection due to
different immune reactions, (ii) physiological incompatibility of the
cells, tissues and organs and (iii) the microbiological risk.
Figure 1: Genetically modified pigs for xenotransplantation.
Overview of the genetically modified pigs for xenotransplantation
(hCD46-human membrane cofactor protein, MCP; hCD55-human
decay-accelerating factor, DAF; hCD59-human protectin; H-
transferase, competing for the substrates needed by the alpha-1,3-
galactosyltranferase; hCTLA4-Ig-human cytotoxic T-murine
lymphocyte antigen 4 fused with Ig heavy chains, as a surrogate ligand
used to block CD28/CTLA4 T-cell costimulation; hTM-human
thrombomodulin, anticoagulation, activates protein C; hA20-tumor
necrosis factor-alpha-(TNF-alpha)-inducible gene, may control the
AVR; HLA-E/beta-microglobulin-protection against human natural
killer cell cytotoxicity, TRAIL-tumor necrosis factor related apoptosis
inducing ligand, induces apoptosis; hHO-1, human heme oxygenase-1,
anti-apoptotic, cell protective, Fas-L-Fas ligand, belongs to the tumor
necrosis factor (TNF) family, its binding with its receptor induces
apoptosis, GnT-III-β-1,4-N acetylglucosaminyltransferase III,
catalyzes the formation of a bisecting GlcNAc structure in N-glycans,
GalTKO-knock-out of the gene for the alpha-1,3-galactosyltranferase,
shRNA PERV-PERV-specific short hairpin RNA, inhibits PERV
expression by RNA interference (for details see [6] and the original
references cited there).
Rejection
Various mechanisms of rejection are associated with
xenotransplantation, the first and most destructive is the hyperacute
rejection (HAR), which is absent in allotransplantation. It is
characterized by an immediate loss of the function of the transplant
and is associated with haemorrhage, thrombosis and infiltration of
neutrophils [19]. HAR is the consequence of the binding of preformed
antibodies to a sugar epitope, the Gal epitope (galactose-alpha-1,3-
galactose), which is present on the cell surface of all bacteria and
mammals with exception of humans, apes and Old world monkeys.
The loss of the Gal epitope was certainly an enormous evolutionary
advantage since it allowed effective protection from microorganisms
and cells from other species. The pre-existing anti-Gal antibodies
destroy together with the complement T-cells carrying the Gal epitope
[20]. Since depletion of anti-Gal antibodies using affinity columns
bearing Gal, depletion of complement by cobra venom factor, or
inhibition of the complement cascade by soluble complement receptor
1 (CR1) or anti-C5 antibodies are not very effective [21,22]{Cascalho,
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Table 1: Strategies to overcome rejection and physiological
incompatibility: Genetically modified pigs.
There are three strategies to overcome HAR by genetic modification
of the pigs: (i) expression of the human complement regulatory
proteins such as hCD59 (protectin), human decay-accelerating factor
(DAF, hCD55) and membrane cofactor protein (MCP, hCD46), (ii)
overexpression of enzymes such as H-transferase, competing for the
substrates needed by the alpha-1,3-galactosyltranferase, which is
responsible for the Gal epitope, and (iii) knock-out of the gene for the
alpha-1,3-galactosyltranferase (GalTKO), these animals are unable to
express the Gal epitope [23,56] (Figure 1). Using multitransgenic pigs
and antibody depletion, HAR, once considered the most vexing
problem for xenotransplantation, was thought to be overcome.
However, meanwhile new carbohydrate non-Gal epitopes have been
identified, which may play a role in HAR [57]. Nevertheless, when
genetically modified pig hearts were transplanted heterotopically in
baboons, a significantly reduced HAR and a survival of up to 8 months
was observed. It is important to note that in contrast orthotopic life
supporting heart transplantation has not extended beyond 57 days.
Similar differences between ortho- and heterotopical-transplantations
were observed when kidneys were transplanted (for review see [58]).
Concerning the next steps of rejection, there is still uncertainty,
both in understanding the mechanisms as well as in naming the
processes: acute vascular rejection (AVR) thought to be similar to
AVR of allotransplants [59], delayed xenograft rejection (DXR) [60],
or acute humoral xenograft rejection (AHXR) [61], a delayed form of
antibody mediated rejection. Endothelial cells and antibodies are
involved in this type of rejection. Finally, the classical cellular rejection
has been described [58]. Rejection on this stage is based on the genetic
differences between humans and pigs and may be controlled by
immunosuppressive regimens more intense than the one used in
allotransplantation. Transgenic pigs expressing CTLA4-Ig to provide a
local immunosuppressive effect or a mutant MHC class II
transactivator (CIITA) knocking down SLA expression in the
endothelium, may be useful (for details see [58]).
Now it becomes clear that coagulation dysfunction between
recipient and donor as well as inflammation contribute significantly to
the loss of the transplant [62]. The induced thrombotic
microangiopathy causes ischemic injury to the myocardium during
heart transplantations and finally results in consumptive coagulopathy
[63,64]. It is still unclear which part is contributed by the immune
activation of the pig vascular endothelial cells or whether the presence
of these cells is sufficient to activate primate/human platelets and
PBMCs alone [65]. The expression of both the pig tissue factor and the
primate tissue factor is increased [65,66]. In the regulation of the
immune response, activating and inhibitory receptors and ligands are
involved and it should be possible in future to knock out certain of
these factors and to develop in vitro assays predicting whether the
recipient is at high or low risk for rejection [67].
Liver and kidney transplantations showed a lower survival time
compared with heart and kidney transplantations (see above). Cellular
transplants, e.g, isle T-cells, function much better than organ
transplants [68,69]. Transplanting pig isle T-cells, either an
immunosuppressive regimen was applied, or the pig isle T-cells were
encapsulated [70,71]. One report indicates that pig isle T-cells survived
up to 9.5 year in the human recipient [72]. Other cell transplantations
include pig neuronal cell xenotransplantation for the treatment of
neurological diseases including Parkinson´s disease [73], and pig
corneal transplantation (for review see [74]).
Physiological Compatibility
Assuming that the immune and physiological mechanisms of
rejection are under control and that the tissues or organs were not
rejected, additional physiological incompatibilities in the function and
regulation can be expected [75]. These incompatibilities are not well
studied and will become evident only when the xenotransplants
survive for a longer time. The differences between pig and human
organs include their size, their position and orientation in the body,
and the mechanism of regulation of their function by hormones and
other soluble factors. On the other hand there are common
physiological processes, e.g., pig insulin has been used for the
treatment of diabetes in humans for decades. Under discussion is the
compatibility of pig erythropoietin produced in the kidney [76]. In the
case it is not compatible, either transgenic pigs producing human
erythropoietin have to be produced or human erythropoietin has to be
injected after kidney transplantation. The liver produces more than
2000 factors including albumin and it seems unlikely that a pig liver
will be functioning for a long period. In addition, ex vivo treatment of
human blood with pig liver cells have resulted in unsatisfying results
[77]. However, when livers from of genetically modified pigs (CD55 or
GalTKO plus CD46) were transplanted into non-human primates,
survival times up to 7 days were observed with near-normal function
of the organ, except hypoalbuminemia, suggesting application as a
bridge to allotransplantation [77].
Microbiological Safety
Xenotransplantation using pig cells, tissues or organs may be
associated with the transmission of numerous porcine microorganisms
and several strategies have been developed to increase the
microbiological safety (Table 2). Long lists have been published with
the names of pig parasites, fungi, bacteria, and viruses, representing a
potential risk for the transplant recipient, especially when strong
pharmaceutical immunosuppression is applied [78]. However, at
present it is unknown which microorganism represent a real risk,
inducing, when transmitted, a disease (zoonosis or xenozoonosis or
xenosis). Breeding the animals under designated pathogen free (dpf)
conditions will prevent at least the transmission of known zoonotic
microorganisms such as circoviruses, herpesviruses and others [79].
Porcine cytomegalovirus (PCMV), porcine lymphotropic herpesvirus
(PLHV), and porcine circovirus (PCV) are the main viruses screened
for in the ongoing New Zealand clinical trial [80,81].
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in the donor pigs [82-86]
Selection of pigs with
low expression of
PERV-A and PERV-B
and absence of PERV-
C in the genome
Prevent PERV-A/C
recombination, low expression,





Low expression, possibly no
particle release [89-92]
Zinc finger nucleases
(ZFN) Attempt to eliminate all PERV [93]
Vaccine Prevent transmission of PERV [94-98]
Antiretroviral drugs Prevention/therapy [99,100]
Table 2: Strategies to increase microbiological safety.
In contrast to these microorganisms transmission of porcine
endogenous retroviruses (PERVs) cannot be prevented by dpf
breeding since they are integrated as DNA copy in the genome of all
pigs [101]. PERVs can be released as infectious particles and infect
human cells [102,103]. Retroviruses are able-using the enzyme reverse
transcriptase which is unique for retroviruses-to transcribe their RNA
genome into DNA and integrate the DNA copy into the genome of the
infected host T-cell. In the case oocytes, sperms or their progenitors
were infected, the integrated DNA copy, also called provirus, will be
present in the fertilized oocyte and eventually in all cells of the
developing organism and will be inherited like a cellular gene.
Gamma- and betaretroviruses were found in the genome of all pigs
[104,105]. The copy number ranges in dependence of the pig strain
from 30 to 150 [105]. Two types of gamma retroviruses, PERV-A and
PERV-B, are present in all pigs, a third, PERVs-C, is present in many,
but not all pigs. PERV-A and -B infect human cells, PERVs-C infect
only pig cells [102]. Retroviruses may induce in the infected host
severe immunosuppression (example: HIV-1 and the feline leukaemia
virus, FeLV), and/or leukemias, lymphomas or solid tumors (example:
HTLV, FeLV) [8-10]. In rare cases retroviral infections are
apathogenic (example: feline and primate foamy viruses) [106].
Transspecies transmissions of retroviruses are well known (for review
see [18]) and the AIDS pandemic is the most disastrous example of a
transmission of a zoonotic retrovirus to humans [10]. PERV is also the
result of a transspecies transmission, probably from rodents [12,13].
PERV-A and PERV-B integrated 8 mio years ago, PERVs-C is younger
and integrated 3 mio years ago [13,107]. Recombinant PERVs-A/C
proviruses were detected in pigs in some tissues, but not in the germ
line (for review see [108]). These viruses have a high replication rate,
they infect human cells and can adapt to them with an increased titer
[109,110].
To detect PERV and to prevent transmission, (i) sensitive and
specific detection methods based on PCR or other molecular biological
methods as well as indirect detection methods measuring PERV-
specific antibody responses, and (ii) strategies how to screen donor
animals and how to follow the recipient have been developed in the
last years [80,81,87,88,99,101,102,105,107-114]. There are
recommendations of the International Xenotransplantion Association
(IXA), the European Medicines Agency (EMA) and the Food and
Drug Administration (FDA) how to screen the donor pigs and how
the recipient of the xenotransplant [82-86,115]. In addition, strategies
how to minimize PERV transmission are under development. These
strategies include the selection of PERV-C free animals (in order to
prevent the generation of high titer PERV-A/C) [88,111], the selection
of pigs with low expression of PERV-A and -B [111,116], the
treatment with antiretrovirals [99,100], the development of a vaccine
[94-98] and the generation of transgenic pigs expressing a short
hairpin RNA in order to suppress the expression of PERV by RNA
interference [89-92] (Figure 1).
Figure 2: Examples of xenotransplantation.
Overview of clinically applied or planned xenotransplantations in
order to treat different diseases. Cells or organs were directly
transplanted into the human organism or pig cells or organs were used
ex vivo to interact with human blood.
First Preclinical and Clinical Trials
Preclinical trials mainly using non-human primates have been
performed in order to evaluate the efficacy and safety of
xenotransplantation (Table 3).
In addition, in the past years more than 200 individuals had
undergone xenotransplantation, mostly ex vivo perfusions with pig
liver and spleen cells and some transplantations of pig islet and
neuronal cells (for a detailed review see [6,83]) (Figure 2) (Table 4).
Organs (heart, liver) were transplanted in two cases with a survival
time of less than 34 hrs (for an overview of the history of
xenotransplantation see [6]). PERVs or other porcine microorganisms
have not been found transmitted until now.
Pig isle T-cells have been transplanted to diabetic individuals in
several trials. In one trial performed in Russia, in two of eight persons
a 100% insulin dose reduction was achieved after the first transplant
[135]. A second trial was performed in New Zealand and in both trials
no transmission of PERV was observed [81,114]. When pig cells or
organs were transplanted into non-human primates (for review see
[83]) or when high doses of infectious PERV were inoculated into
non-human primates [85], no transmission of PERV was observed
despite strong pharmaceutical immunosuppression in most cases.
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Xenotransplantation: Strategy




one animal also pig heart, Cyp
None 15 baboons
No PERV transmission and no
microchimerism 1 year after
treatment, 12-24 months
[117]
Heart, skin, encapsulated islets,
some CsA, MMF, Ster None
23 (6 baboons, 6 bonnet macaques, 9
STZ rhesus, 2 STZ capuchins
No PERV transmission, 11-31
months [118]
Kidney, Cyp, CsA, MMF, Ster hCD59 6 cynomolgus monkey No PERV transmission, 1-19 days [119]
Kidney  12 cynomolgus monkey No PERV transmission, transplantremoved days 2-15, up to day 287 [120]
Encapsulated isleT-cells, no
immunosuppression None 12 STZ cynomolgus monkey
No transmission of PERV and other
viruses, 3-8 months [80]
Kidney (13) or heart (14)
GAS914, Cyp, CsA, MPA hDAF 27 baboons No PERV transmission, 6-50 days [121]
Liver perfusion 13-24 hours
without immunosuppression hDAF 6 baboons
No PERV transmission, 6-12
months [122]





3 baboons Reduced xenoantibody response toisle T-cells from transgenic animals [49]





5 non-diabetic baboons No coagulation incompatibilities, nothrombosis [51]
Abbreviations: C1inh, complement C1 inhibitor; CsA, Cyclosporine A; CyP, cyclophosphamide; EC, endothelial cells; FTBI, fractionated total body irradiation; GAS914,
a soluble, polymeric form of a Gal alpha-(1,3)Gal trisaccharide, hDAF, human decay-accelerating factor; MPA, mycophenolic acid; PAEC, primary aortic endothelial
cells; Ster, steroids; STZ, streptocotozin (induced diabetes), Tx, transplantation.









Acute liver failure Bioartificial liver device,
90-100 g wet weight
None 6 hrs pre/post 6 No PERV transmission [123]
Cryopreserved
hepatocytes
N=2 for liver-tx after
procedure
3 months – 5 yrs
post treatment
28 No PERV transmission [124]
AMC-BAL Before, 0 days to 2
yrs after
14 No PERV transmission [125,126]
Plasma perfusion though
bioreactor
Followed by liver Tx +
immunosuppression



























No PERV transmission [130]
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Diabetes Encapsulated islets No IS (n=1)
CsA, AZA, pred (n=1) for
kidney Tx
19 months 2 No PERV transmission [131]
Porcine fetal islets, 4x108
– 2x109 cells








(n=1), d3 (n=6): all
had Abs within 1wk
post-Tx
10 No PERV transmission [132]
Beginning in 2009 treated
with one of four different
dosages of alginate-
encapsulated porcine
islets ranging from 5,000
- 20,000 IEQ/kg delivered
in a single dose









Acute liver failure Cryopreserved
hepatocytes
Exposure 2 – 30 hours No PERV
transmission




Exposure 4.25 hours, IS










Exposure 35, 65 min 32-36 months 2
Various indications Extracorporeal splenic
perfusion
Exposure 50-60 min 0-102 months 100
Diabetes Islets 19-93 months 14
Abbreviations: Abs, antibodies; AMC-BAL, Academic Center in Amsterdam, BAL, bio-artificial liver; CsA, cyclosporine; AZA, azathioprine; IS, immunosuppression;
PBMC, peripheral blood mononuclear cells; pred, prednisolone; Ster, steroids; Tx, transplantation; PD, Parkinson´s disease; HD, Huntington´s disease; FE, focal
epilepsy
Table 4: Clinical xenotransplantations.
Ethical Aspects and Regulatory Requirements
Xenotransplantation is on the way from the lab to the clinic [135].
The ethical discussion came to the conclusion that this new technology
should be applied if it is safe and effective [115]. The regulatory issues
(informed consent, criteria for patient enrollment, the rights and
obligations of third parties, the ethical management of safety
measures, and the use of animals) remain central and the public health
risk represents a major concern. After it was documented that PERVs
infect human cells, it was perceived-mainly based on the knowledge
that the infection of humans with HIV and the AIDS pandemic were
the result of a trans-species transmission of this retrovirus-
xenotransplantation might create a new epidemic infectious disease.
Meanwhile the ethical concerns are minimal as (i) no transmission of
PERVs was observed in the first clinical xenotransplantations, (ii) no
transmission of PERV was observed in experimental settings and (iii)
pigs are a major source of animal protein throughout the world. The
International Xenotransplantation Association (IXA) [83,84,115], the
European Medicines Agency (EMA) [85], and the US Food and Drug
Administration (FDA) [86] developed appropriate guidelines how to
perform clinical xenotransplantations.
Conclusion
Xenotransplantation may have several advantages compared with
allotransplantation. It may overcome the shortage of organs, the
transplantations can be planned, the organs are in a good status and
well characterized, the microbiological risk may be low (note that HIV,
rabies virus, Epstein-Barr virus, cytomegalovirus and other viruses had
been transmitted repeatedly during allotransplantations) [136,137]. In
the first clinical trials, isle T-cells from Auckland island pigs were used
which were well defined concerning the microorganisms they carry
[80,81,87]. Meanwhile the Göttingen minipigs are also well
characterized [93], although additional tests for some relevant
microorganisms have to be performed [138]. Due to their small size
these animals are not suitable for organ transplantations, but certainly
for isle T-cell transplantations for the treatment of diabetes.
On the other hand there is still a long way to go to solve the
problems concerning rejection, physiological compatibility and
microbiological safety. Looking back to the origins of
allotransplantation 40 years ago, it would be interesting to see how far
xenotransplantation will be advanced in 40 years from now.
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